Anti-cancer vaccine candidates in specific immunotherapy for bladder carcinoma

Yoshihiro Komohara, Mamoru Harada, Yoshimi Arima, Shigetaka Suekane, Masanori Noguchi, Akira Yamada, Kyogo Itoh, Kei Matsuoka

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

We have previously identified numerous tumor-rejection antigens and their epitope peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes (CTLs) in patients with various types of cancer. In the present study, we attempted to determine which antigens and their peptides are useful in specific immunotherapy for bladder carcinoma (BC) patients, especially those with human leukocyte antigen (HLA)-A24+ alleles. The mRNA expression of a panel of cancer-associated antigens was examined regarding four BC cell lines. As a result, three candidate antigens, including SART3, multidrug resistance-associated protein 3 (MRP3), and polycomb group protein enhancer of zeste homolog 2 (EZH2), were expressed in three of four BC cell lines. Thereafter, antigen-derived peptides which we reported to induce cancer-reactive CTLs from HLA-A24+ patients with various types of cancer were examined for their potential to induce CTLs from peripheral-blood mononuclear cells of HLA-A24+ BC patients. Among these antigen-derived six peptides, SART3109-118, MRP31293-1301, and EZH2 735-742 peptides efficiently induced peptide-specific and BC cell-reactive CTLs from HLA-A24+ BC patients. The cytotoxicity against BC cells was dependent on peptide-specific CD8+ T cells. IgG reactive to the SART3109-118 peptide was frequently detected in the plasma of BC patients. This information could facilitate the development of effective peptide-based immunotherapy for HLA-A24+ BC patients.

Original languageEnglish
Pages (from-to)1555-1560
Number of pages6
JournalInternational Journal of Oncology
Volume29
Issue number6
Publication statusPublished - 2006 Dec 1
Externally publishedYes

Fingerprint

Cancer Vaccines
Immunotherapy
Urinary Bladder
Carcinoma
Peptides
HLA Antigens
Cytotoxic T-Lymphocytes
Antigens
Neoplasms
Polycomb-Group Proteins
Cell Line
Neoplasm Antigens
Epitopes
Blood Cells
Immunoglobulin G
Alleles
T-Lymphocytes
Messenger RNA

Keywords

  • Bladder cancer
  • EZH2
  • HLA-A24
  • MRP3
  • Peptide vaccine
  • SART3

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Komohara, Y., Harada, M., Arima, Y., Suekane, S., Noguchi, M., Yamada, A., ... Matsuoka, K. (2006). Anti-cancer vaccine candidates in specific immunotherapy for bladder carcinoma. International Journal of Oncology, 29(6), 1555-1560.

Anti-cancer vaccine candidates in specific immunotherapy for bladder carcinoma. / Komohara, Yoshihiro; Harada, Mamoru; Arima, Yoshimi; Suekane, Shigetaka; Noguchi, Masanori; Yamada, Akira; Itoh, Kyogo; Matsuoka, Kei.

In: International Journal of Oncology, Vol. 29, No. 6, 01.12.2006, p. 1555-1560.

Research output: Contribution to journalArticle

Komohara, Y, Harada, M, Arima, Y, Suekane, S, Noguchi, M, Yamada, A, Itoh, K & Matsuoka, K 2006, 'Anti-cancer vaccine candidates in specific immunotherapy for bladder carcinoma', International Journal of Oncology, vol. 29, no. 6, pp. 1555-1560.
Komohara Y, Harada M, Arima Y, Suekane S, Noguchi M, Yamada A et al. Anti-cancer vaccine candidates in specific immunotherapy for bladder carcinoma. International Journal of Oncology. 2006 Dec 1;29(6):1555-1560.
Komohara, Yoshihiro ; Harada, Mamoru ; Arima, Yoshimi ; Suekane, Shigetaka ; Noguchi, Masanori ; Yamada, Akira ; Itoh, Kyogo ; Matsuoka, Kei. / Anti-cancer vaccine candidates in specific immunotherapy for bladder carcinoma. In: International Journal of Oncology. 2006 ; Vol. 29, No. 6. pp. 1555-1560.
@article{8abe11d4473d469d8d2e1595b8e894f0,
title = "Anti-cancer vaccine candidates in specific immunotherapy for bladder carcinoma",
abstract = "We have previously identified numerous tumor-rejection antigens and their epitope peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes (CTLs) in patients with various types of cancer. In the present study, we attempted to determine which antigens and their peptides are useful in specific immunotherapy for bladder carcinoma (BC) patients, especially those with human leukocyte antigen (HLA)-A24+ alleles. The mRNA expression of a panel of cancer-associated antigens was examined regarding four BC cell lines. As a result, three candidate antigens, including SART3, multidrug resistance-associated protein 3 (MRP3), and polycomb group protein enhancer of zeste homolog 2 (EZH2), were expressed in three of four BC cell lines. Thereafter, antigen-derived peptides which we reported to induce cancer-reactive CTLs from HLA-A24+ patients with various types of cancer were examined for their potential to induce CTLs from peripheral-blood mononuclear cells of HLA-A24+ BC patients. Among these antigen-derived six peptides, SART3109-118, MRP31293-1301, and EZH2 735-742 peptides efficiently induced peptide-specific and BC cell-reactive CTLs from HLA-A24+ BC patients. The cytotoxicity against BC cells was dependent on peptide-specific CD8+ T cells. IgG reactive to the SART3109-118 peptide was frequently detected in the plasma of BC patients. This information could facilitate the development of effective peptide-based immunotherapy for HLA-A24+ BC patients.",
keywords = "Bladder cancer, EZH2, HLA-A24, MRP3, Peptide vaccine, SART3",
author = "Yoshihiro Komohara and Mamoru Harada and Yoshimi Arima and Shigetaka Suekane and Masanori Noguchi and Akira Yamada and Kyogo Itoh and Kei Matsuoka",
year = "2006",
month = "12",
day = "1",
language = "English",
volume = "29",
pages = "1555--1560",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "6",

}

TY - JOUR

T1 - Anti-cancer vaccine candidates in specific immunotherapy for bladder carcinoma

AU - Komohara, Yoshihiro

AU - Harada, Mamoru

AU - Arima, Yoshimi

AU - Suekane, Shigetaka

AU - Noguchi, Masanori

AU - Yamada, Akira

AU - Itoh, Kyogo

AU - Matsuoka, Kei

PY - 2006/12/1

Y1 - 2006/12/1

N2 - We have previously identified numerous tumor-rejection antigens and their epitope peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes (CTLs) in patients with various types of cancer. In the present study, we attempted to determine which antigens and their peptides are useful in specific immunotherapy for bladder carcinoma (BC) patients, especially those with human leukocyte antigen (HLA)-A24+ alleles. The mRNA expression of a panel of cancer-associated antigens was examined regarding four BC cell lines. As a result, three candidate antigens, including SART3, multidrug resistance-associated protein 3 (MRP3), and polycomb group protein enhancer of zeste homolog 2 (EZH2), were expressed in three of four BC cell lines. Thereafter, antigen-derived peptides which we reported to induce cancer-reactive CTLs from HLA-A24+ patients with various types of cancer were examined for their potential to induce CTLs from peripheral-blood mononuclear cells of HLA-A24+ BC patients. Among these antigen-derived six peptides, SART3109-118, MRP31293-1301, and EZH2 735-742 peptides efficiently induced peptide-specific and BC cell-reactive CTLs from HLA-A24+ BC patients. The cytotoxicity against BC cells was dependent on peptide-specific CD8+ T cells. IgG reactive to the SART3109-118 peptide was frequently detected in the plasma of BC patients. This information could facilitate the development of effective peptide-based immunotherapy for HLA-A24+ BC patients.

AB - We have previously identified numerous tumor-rejection antigens and their epitope peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes (CTLs) in patients with various types of cancer. In the present study, we attempted to determine which antigens and their peptides are useful in specific immunotherapy for bladder carcinoma (BC) patients, especially those with human leukocyte antigen (HLA)-A24+ alleles. The mRNA expression of a panel of cancer-associated antigens was examined regarding four BC cell lines. As a result, three candidate antigens, including SART3, multidrug resistance-associated protein 3 (MRP3), and polycomb group protein enhancer of zeste homolog 2 (EZH2), were expressed in three of four BC cell lines. Thereafter, antigen-derived peptides which we reported to induce cancer-reactive CTLs from HLA-A24+ patients with various types of cancer were examined for their potential to induce CTLs from peripheral-blood mononuclear cells of HLA-A24+ BC patients. Among these antigen-derived six peptides, SART3109-118, MRP31293-1301, and EZH2 735-742 peptides efficiently induced peptide-specific and BC cell-reactive CTLs from HLA-A24+ BC patients. The cytotoxicity against BC cells was dependent on peptide-specific CD8+ T cells. IgG reactive to the SART3109-118 peptide was frequently detected in the plasma of BC patients. This information could facilitate the development of effective peptide-based immunotherapy for HLA-A24+ BC patients.

KW - Bladder cancer

KW - EZH2

KW - HLA-A24

KW - MRP3

KW - Peptide vaccine

KW - SART3

UR - http://www.scopus.com/inward/record.url?scp=39049185212&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39049185212&partnerID=8YFLogxK

M3 - Article

VL - 29

SP - 1555

EP - 1560

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 6

ER -